HLB생명과학

067630KOSDAQ

54.1 / 100

Reference Date: 2026-09-08

Financial Score18.0 / 40

News Sentiment18.1 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 6.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

HLB Life Science operates four business divisions: Medicare, Biotech Development, Medical Device, and Energy, focusing on medical device manufacturing, pharmaceutical R&D, disposable syringe production, and solar EPC projects. Key clients include Abbott and Roche, and the company expanded its medical device market through the 2023 merger with Hwa Jin Medical and acquisition of Tinyco, which specializes in medical-grade nickel-titanium alloys.

Number of Employees

180people

Average Salary

48.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

1.09Industry Average 1.204.0Point

In line with industry avg

ROE

-28.70Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

20.67Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼25.5% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲5.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -9.8% (declining, 3yr)

Detailed News Sentiment

10 totalPositive 6Neutral 3Negative 1Average Sentiment Score 72.5

Negative
HLB생명과학, 계열사 지원에 CB 상환까지…재무 부담 확대
HLB생명과학이 계열사 자금 조달을 위해 주식 매각과 유증 참여로 인해 재무 부담이 증가했다.
Neutral
HLB이노베이션, HLB생명과학 대상 360억원 유상증자 결정
HLB이노베이션의 유상증자 결정으로 인해 HLB생명과학과 관련된 자금 조달 계획이 발표되었으나, 직접적인 영향은 제한적임.
Positive
FDA 심사 앞둔 HLB, 계열사 교통정리…상업화 채비
HLB생명과학은 FDA 승인을 앞두고 계열사 재편을 통해 신약 개발 효율성 향상에 집중하고 있다.

Detailed Momentum

52-week position3.0Point

52w lower range (29%)

Current 2,660Won52-week high 5,15052-week low 1,640

1-month return4.0Point

1m +6.40% (slight rise)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

6 totalPositive 0Neutral 6Negative 0

Neutral전환사채(해외전환사채포함)발행후만기전사채취득 (제13회차)2026-08-31
Neutral타법인주식및출자증권취득결정2026-08-28
Neutral타법인주식및출자증권처분결정2026-08-26
Neutral교환가액의조정 (제16회차)2026-08-20
Neutral전환사채(해외전환사채포함)발행후만기전사채취득 (제13회차)2026-08-14